ArticleBlood2012
How I treat childhood CML.
Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 99 citations in OpenAlex.
- Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib.Bone marrow transplantation · 2014Trial
- Favorable outcomes of de novo advanced phases of pediatric chronic myeloid leukemia in the tyrosine kinase inhibitor era.International journal of hematology · 2025Article
- Cases of Patients Treated in Countries With Limited Resources and Discussed by Experts of the International CML Foundation (iCMLf)-Case No. 2: Treatment-Free Remission After 9 Years of Imatinib Treatment Without Prior Achievement of Sustained Deep Molecular Response.Case reports in oncological medicine · 2025Article
- Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course.Annals of hematology · 2023Article
- Outcome prediction of chronic myeloid leukemia (CML) in children.Annals of hematology · 2022Article
- Modulation of Plasma 25-Hydroxyvitamin D3 Level by Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia: The Role of Uptake and Efflux Transporters.Current therapeutic research, clinical and experimental · 2022Article
- Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review.Frontiers in oncology · 2022Review
- Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China.International journal of hematology · 2021Article
- Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML.International journal of molecular sciences · 2020Review
- Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2020Article
- Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group.Pediatric blood & cancer · 2019Review
- Paediatric chronic myeloid leukaemia: Is it really a different disease?The Indian journal of medical research · 2019Review
- BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2018Review
- Comparative Study of Clinico-hematological Features, Molecular Spectrum and Response to Imatinib in Chronic Myelogenous Leukemia Patients: Pediatric and Adolescent Versus Adults.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2018Article
- Chronic Myeloid Leukemia in India.Journal of global oncology · 2017Review
- The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.Blood · 2015Review
- Treatment of chronic phase chronic myeloid leukemia with imatinib.Indian journal of pediatrics · 2015Article
- Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase.South Asian journal of cancer · 2014Article
- Chronic myeloid leukemia in India: The poster child of translational medicine needs help!South Asian journal of cancer · 2013Article
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Blood · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Chronic myeloid leukemia (CML) is composed of 3% of pediatric leukemias, making evidence-based recommendations difficult. Imatinib has revolutionized the treatment for adult CML by eliminating allogeneic stem cell transplantation for almost all patients in chronic phase. Shown effective in pediatric CML, imatinib and successive tyrosine kinase inhibitors (TKI) have provided more therapeutic options. Because stem cell transplantation has been better tolerated in children and adolescents, the decision to treat by either TKI or transplantation is controversial. We present a recent case of a 12-month-old boy diagnosed with BCR-ABL(+) CML to highlight the controversies in treatment recommendations. We review the pediatric stem cell transplantation outcomes as well as the pediatric experience with imatinib and other TKIs. Finally, we compare the side effects as well as costs associated with allogeneic stem cell transplantation versus TKI therapy. We recommend that frontline therapy for pediatric CML in chronic phase is TKI therapy without transplantation. Patients in accelerated or blast crisis or who fail to reach landmarks on TKIs either because of intolerance or resistance should pursue stem cell transplantation. Although we recommend adopting adult clinical experience to guide therapeutic decision making, the issues of infant CML, drug formulation, pharmacokinetics, and adolescent compliance merit clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.